解放军医学杂志2017，Vol.42Issue(6)：483-487,5.DOI:10.11855/j.issn.0577-7402.2017.06.01
非小细胞肺癌治疗新时代:免疫治疗
Treatment of non-small cell lung cancer comes to the age of immunotherapy
摘要
Abstract
Immune checkpoint inhibitors have become an important alternative for advanced non-small cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted therapy. Monoclonal antibodies directed against immune checkpoint have shown better results in the application of first- or second-line treatment of NSCLC and for both squamous and non-squamous cell carcinoma patients, especially for those with positive PD-L1 tumor cells. Some comments will be made in present paper about the efficacy, biomarker, combined therapy and the resistant mechanism of immune checkpoint inhibitors.关键词
肺癌,非小细胞/免疫治疗/免疫检查点/程序死亡分子1/细胞毒T淋巴细胞抗体4Key words
lung cancer/non-small cell/immunotherapy/immune checkpoint/programmed death protein 1/cytotoxic T-lymphocyte-associated protein 4分类
医药卫生引用本文复制引用
袁冬梅,宋勇..非小细胞肺癌治疗新时代:免疫治疗[J].解放军医学杂志,2017,42(6):483-487,5.基金项目
国家自然科学基金青年科学基金(81602015,81401903) （81602015,81401903）
江苏省自然科学基金青年基金(BK20140736) This work was supported by the National Natural Science Foundation of China (81602015, 81401903), and the Natural Science Foundation of Jiangsu Province (BK20140736) （BK20140736）
